Acadia Pharmaceuticals logo

Acadia Pharmaceuticals Share Price Today

(NASDAQ: ACAD)

Acadia Pharmaceuticals share price is $14.73 & ₹1,258.90 as on 18 Apr 2025, 2.30 'hrs' IST

$14.73

0.16

(1.1%)

Market is closed - opens 7 PM, 21 Apr 2025

View live Acadia Pharmaceuticals share price in Dollar and Rupees. Guide to invest in Acadia Pharmaceuticals stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Acadia Pharmaceuticals, along with analyst recommendations, forecasts, and comprehensive financials.

Acadia Pharmaceuticals share price movements

  • Today's Low: $14.39
    Today's High: $14.73

    Day's Volatility :2.32%

  • 52 Weeks Low: $13.40
    52 Weeks High: $20.68

    52 Weeks Volatility :35.2%

Acadia Pharmaceuticals (ACAD) Returns

PeriodAcadia Pharmaceuticals Inc.Sector (Health Care)Index (Russel 2000)
3 Months
-17.66%
-2.8%
0.0%
6 Months
-0.2%
-11.0%
0.0%
1 Year
-12.43%
-1.9%
0.0%
3 Years
-30.97%
-1.5%
-12.9%

Acadia Pharmaceuticals (ACAD) Key Statistics

in dollars & INR

Previous Close
$14.57
Open
$14.47
Today's High
$14.73
Today's Low
$14.389
Market Capitalization
$2.5B
Today's Volume
$1.2M
52 Week High
$20.68
52 Week Low
$13.4
Revenue TTM
$957.8M
EBITDA
$100.2M
Earnings Per Share (EPS)
$1.36
PE Ratio
10.83
Profit Margin
23.64%
Quarterly Earnings Growth YOY
2.13%
Return On Equity TTM
38.89%

How to invest in Acadia Pharmaceuticals Stock (ACAD) from India?

It is very easy for Indian residents to invest directly in Acadia Pharmaceuticals from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Acadia Pharmaceuticals stock in both Indian Rupees (INR) and US Dollars (USD). Search for Acadia Pharmaceuticals or ACAD on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Acadia Pharmaceuticals or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Acadia Pharmaceuticals shares which would translate to 0.058 fractional shares of Acadia Pharmaceuticals as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Acadia Pharmaceuticals, in just a few clicks!

Returns in Acadia Pharmaceuticals (ACAD) for Indian investors in Rupees

The Acadia Pharmaceuticals stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Acadia Pharmaceuticals investment value today

Current value as on today

₹89,915

Returns

₹10,085

(-10.08%)

Returns from Acadia Pharmaceuticals Stock

₹12,426 (-12.43%)

Dollar Returns

₹2,341 (+2.34%)

Indian investors sentiment towards Acadia Pharmaceuticals (ACAD)

0%

Period: Mar 19, 2025 to Apr 18, 2025. Change in 30 Days versus previous period

Search interest for Acadia Pharmaceuticals Stock from India on INDmoney has increased by 0% in the last 30 days, reflecting an upward trend in search activity.

Global Institutional Holdings in Acadia Pharmaceuticals

  • Baker Bros Advisors LP

    25.71%

  • Vanguard Group Inc

    8.36%

  • BlackRock Inc

    7.63%

  • RTW INVESTMENTS, LLC

    5.22%

  • Morgan Stanley - Brokerage Accounts

    4.38%

  • State Street Corp

    2.71%

Analyst Recommendation on Acadia Pharmaceuticals

Rating
Trend

Buy

    73%Buy

    23%Hold

    3%Sell

Based on 26 Wall street analysts offering stock ratings for Acadia Pharmaceuticals(by analysts ranked 0 to 5 stars)

Analyst Forecast on Acadia Pharmaceuticals Stock (ACAD)

What analysts predicted

Upside of 67.58%

Target:

$24.68

Current:

$14.73

Insights on Acadia Pharmaceuticals Stock (Ticker Symbol: ACAD)

  • Price Movement

    In the last 6 months, ACAD stock has moved down by -4.8%
  • Increasing Revenue

    Revenue is up for the last 4 quarters, 205.83M → 259.60M (in $), with an average increase of 7.3% per quarter
  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, 32.76M → 143.74M (in $), with an average increase of 77.2% per quarter
  • ACAD vs ONC (1 yr)

    In the last 1 year, Beone Medicines Ltd has given 76.1% return, outperforming this stock by 89.5%
  • ACAD vs VRTX (3 yr)

    In the last 3 years, Vertex Pharmaceuticals Incorporated has given 28.9% return, outperforming this stock by 61.8%
  • Price to Sales

    ForACAD every $1 of sales, investors are willing to pay $2.5, whereas for Beone Medicines Ltd, the investors are paying $6.4 for every $1 of sales.

ACAD Acadia Pharmaceuticals Financials in INR & Dollars

Revenue
Profit
Cash Flow
Annually
Quarterly
FY19
FY20
FY21
FY22
FY23
FY24
FY24Y/Y Change
Revenue
$957.8M
↑ 31.85%
Net Income
$226.5M
↓ 469.5%
Net Profit Margin
23.64%
↑ 32.08%

Acadia Pharmaceuticals Technicals Summary

Sell

Neutral

Buy

Acadia Pharmaceuticals is currently in a neutral trading position according to technical analysis indicators.

Acadia Pharmaceuticals (ACAD) Vs Peers

Returns
Ratio's
Overview
Company Name1 Month6 Month1 Year3 Years5 Years
Acadia Pharmaceuticals Inc. logo
-14.26%
-0.2%
-12.43%
-30.97%
-70.38%
Regeneron Pharmaceuticals, Inc. logo
-17.1%
-41.85%
-37.2%
-21.74%
-0.85%
Beone Medicines Ltd logo
-13.12%
5.03%
78.34%
40.23%
43.44%
Vertex Pharmaceuticals Incorporated logo
-4.76%
2.3%
24.05%
71.43%
78.99%
Alnylam Pharmaceuticals, Inc. logo
-9.09%
-19.67%
62.43%
39.66%
61.91%

About Acadia Pharmaceuticals

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin which completed Phase III clinical trial to treat the negative symptoms of schizophrenia; ACP-101, which completed phase III clinical trial for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 that completed phase II clinical trial for the treatment of Alzheimer's disease psychosis and Lewy Body Dementia with psychosis; ACP-711, which is in phase I clinical trial for the treatment of essential tremor; ACP-211 that is in phase I clinical trial for the treatment of treatment-resistant depression; ACP-2591 that is in Phase I development for Rett syndrome and Fragile X syndrome; and ACP-271, a GPR88 agonist used in evaluation of neurology and is in the IND-enabling stage. The company has a license agreement with Neuren Pharmaceuticals Limited to trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.
Organization
Acadia Pharmaceuticals
Employees
653
CEO
Ms. Catherine E. Owen Adams
Industry
Health Technology

Management People of Acadia Pharmaceuticals

NameTitle
Mr. Mark C. Schneyer
Executive VP & CFO
Mr. Stephen R. Davis J.D.
Consultant
Ms. Catherine E. Owen Adams
CEO & Director
Dr. Elizabeth H.Z. Thompson Ph.D.
Head of Research & Development
Ms. Jennifer J. Rhodes J.D.
Chief Legal Officer & Secretary
Mr. Rob Ackles
Chief People Officer
Mr. James K. Kihara
Senior Vice President of Finance
Dr. Kevin R. Oliver Ph.D.
Chief Business Officer
Mr. Thomas Andrew Garner
Chief Commercial Officer

Important FAQs about investing in ACAD Stock from India :

What is Acadia Pharmaceuticals share price today?

Acadia Pharmaceuticals share price today stands at $14.73, Open: $14.47 ; Previous Close: $14.57 ; High: $14.73 ; Low: $14.39 ; 52 Week High: $20.68 ; 52 Week Low: $13.40.

The stock opens at $14.47, after a previous close of $14.57. The stock reached a daily high of $14.73 and a low of $14.39, with a 52-week high of $20.68 and a 52-week low of $13.40.

Can Indians buy Acadia Pharmaceuticals shares?

Yes, Indians can invest in the Acadia Pharmaceuticals (ACAD) from India.

With INDmoney, you can buy Acadia Pharmaceuticals at 0 brokerage. The step-by-step process is as follows:

  • Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
  • Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
  • Once funds are transferred successfully, you can buy Acadia Pharmaceuticals at zero transaction cost.

How can I buy Acadia Pharmaceuticals shares from India?

It is very easy to buy Acadia Pharmaceuticals from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Acadia Pharmaceuticals (ACAD) be purchased?

Yes, you can buy fractional shares of Acadia Pharmaceuticals with INDmoney app.

What are the documents required to start investing in Acadia Pharmaceuticals stocks?

To start investing in Acadia Pharmaceuticals, You will need the following documents:

  • Proof of Identification (PAN, Aadhaar etc)
  • Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.

What are today’s High and Low prices of Acadia Pharmaceuticals Stock (ACAD)?

Today’s highest price of Acadia Pharmaceuticals (ACAD) is $14.73.

Today’s lowest price of Acadia Pharmaceuticals (ACAD) is $14.39.

What is today's market capitalisation of Acadia Pharmaceuticals?

Today's market capitalisation of Acadia Pharmaceuticals ACAD is 2.5B

What is the 52 Week High and Low Range of Acadia Pharmaceuticals Stock (ACAD)?

  • 52 Week High

    $20.68

  • 52 Week Low

    $13.40

What are the historical returns of Acadia Pharmaceuticals (ACAD)?

  • 1 Month Returns

    -14.26%

  • 3 Months Returns

    -0.2%

  • 1 Year Returns

    -12.43%

  • 5 Years Returns

    -70.38%

Who is the Chief Executive Officer (CEO) of Acadia Pharmaceuticals ?

Ms. Catherine E. Owen Adams is the current Chief Executive Officer (CEO) of Acadia Pharmaceuticals.